Literature DB >> 12218715

Obsessive compulsive disorder in huntington disease: a case of isolated obsessions successfully treated with sertraline.

Tanja Patzold1, Martin Brüne.   

Abstract

OBJECTIVE: To report about a patient with Huntington disease (HD) in combination with obsessions who was successfully treated with a selective serotonin reuptake inhibitor.
BACKGROUND: Obsessive compulsive disorder (OCD) has rarely been reported in association with HD, and little is known about the treatment of patients with OCD symptoms and HD.
METHODS: We describe a 42-year-old woman who experienced isolated obsessive thoughts about killing her neighbor 10 years after the onset of her genetically confirmed HD.
RESULTS: Sertraline was prescribed at a daily dose of 150 mg with a complete remission of obsessive ideas within 4 weeks of treatment.
CONCLUSIONS: The basal ganglia are known to play an important role in the pathogenesis of OCD and HD. Thus, it is conceivable that a degeneration of the caudate nucleus as in HD may also account for obsessive and compulsive symptoms in this disorder. To our knowledge, this is the first report about a patient with HD in combination with obsessions alone who was successfully treated with a selective serotonin reuptake inhibitor. However, the association of OCD with HD warrants further systematic evaluation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12218715

Source DB:  PubMed          Journal:  Neuropsychiatry Neuropsychol Behav Neurol        ISSN: 0894-878X


  10 in total

1.  Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.

Authors:  Wenzhen Duan; Qi Peng; Naoki Masuda; Eric Ford; Erik Tryggestad; Bruce Ladenheim; Ming Zhao; Jean Lud Cadet; John Wong; Christopher A Ross
Journal:  Neurobiol Dis       Date:  2008-03-10       Impact factor: 5.996

2.  Patterns of serotonergic antidepressant usage in prodromal Huntington disease.

Authors:  Kelly C Rowe; Jane S Paulsen; Douglas R Langbehn; Chiachi Wang; James Mills; Leigh J Beglinger; Megan M Smith; Eric A Epping; Jess G Fiedorowicz; Kevin Duff; Adam Ruggle; David J Moser
Journal:  Psychiatry Res       Date:  2012-03-05       Impact factor: 3.222

Review 3.  Huntington's Disease-Update on Treatments.

Authors:  Kara J Wyant; Andrew J Ridder; Praveen Dayalu
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

Review 4.  Current and Possible Future Therapeutic Options for Huntington's Disease.

Authors:  Mackenzie W Ferguson; Connor J Kennedy; Thulani H Palpagama; Henry J Waldvogel; Richard L M Faull; Andrea Kwakowsky
Journal:  J Cent Nerv Syst Dis       Date:  2022-05-21

5.  Obsessive-Compulsive Disorder Symptoms in Huntington's Disease: A Case Report.

Authors:  Juan Carlos Molano-Eslava; Angela Iragorri-Cucalón; Gonzalo Ucrós-Rodríguez; Carolina Bonilla-Jácome; Santiago Tovar-Perdomo; David V Herin; Luis Orozco-Cabal
Journal:  Rev Colomb Psiquiatr       Date:  2008-10-01

Review 6.  Symptomatic treatment of Huntington disease.

Authors:  Octavian R Adam; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

7.  An International Survey-based Algorithm for the Pharmacologic Treatment of Obsessive-Compulsive Behaviors in Huntington's Disease.

Authors:  Karen Anderson; David Craufurd; Mary C Edmondson; Nathan Goodman; Mark Groves; Erik van Duijn; Daniel P van Kammen; Lavonne Goodman
Journal:  PLoS Curr       Date:  2011-09-20

8.  Huntington's Disease and Striatal Signaling.

Authors:  Emmanuel Roze; Emma Cahill; Elodie Martin; Cecilia Bonnet; Peter Vanhoutte; Sandrine Betuing; Jocelyne Caboche
Journal:  Front Neuroanat       Date:  2011-08-23       Impact factor: 3.856

9.  Obsessive-Compulsive and Perseverative Behaviors in Huntington's Disease.

Authors:  Mayke Oosterloo; David Craufurd; Hanneke Nijsten; Erik van Duijn
Journal:  J Huntingtons Dis       Date:  2019

10.  International Guidelines for the Treatment of Huntington's Disease.

Authors:  Anne-Catherine Bachoud-Lévi; Joaquim Ferreira; Renaud Massart; Katia Youssov; Anne Rosser; Monica Busse; David Craufurd; Ralf Reilmann; Giuseppe De Michele; Daniela Rae; Ferdinando Squitieri; Klaus Seppi; Charles Perrine; Clarisse Scherer-Gagou; Olivier Audrey; Christophe Verny; Jean-Marc Burgunder
Journal:  Front Neurol       Date:  2019-07-03       Impact factor: 4.086

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.